These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10187039)

  • 61. OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIII.
    Toschi V
    Curr Opin Mol Ther; 2010 Oct; 12(5):617-25. PubMed ID: 20886394
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.
    Batlle J; Gómez E; Rendal E; Torea J; Lourés E; Couselo M; Vila P; Sedano C; Tusell X; Magallón M; Quintana M; González-Boullosa R; López-Fernández MF
    Ann Hematol; 1996 May; 72(5):321-6. PubMed ID: 8645745
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII.
    Barrow RT; Lollar P
    J Thromb Haemost; 2006 Oct; 4(10):2223-9. PubMed ID: 16856973
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Factor VIII therapy for hemophilia A: current and future issues.
    Aledort L; Ljung R; Mann K; Pipe S
    Expert Rev Hematol; 2014 Jun; 7(3):373-85. PubMed ID: 24717090
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Successful use of recombinant factor VIIa for emergency fasciotomy in a patient with hemophilia A and high-titer inhibitor unresponsive to factor VIII inhibitor bypassing activity.
    Watts RG
    Am J Hematol; 2005 May; 79(1):58-60. PubMed ID: 15849767
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Agarose gel method: its usefulness in assaying factor VIII inhibitors, evaluating treatment and suggesting a mechanism of action for factor IX concentrates.
    Coots MC; Glueck HI; Miller MA
    Br J Haematol; 1985 Aug; 60(4):735-50. PubMed ID: 3927972
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group.
    Aygören-Pürsün E; Scharrer I
    Thromb Haemost; 1997 Nov; 78(5):1352-6. PubMed ID: 9408018
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Previously untreated patients and recombinant factor VIII concentrate studies.
    Pasi KJ
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S29-32. PubMed ID: 9351534
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inhibitor questions: plasma-derived factor VIII and recombinant factor VIII.
    Bray G
    Ann Hematol; 1994; 68 Suppl 3():S29-34. PubMed ID: 8180254
    [No Abstract]   [Full Text] [Related]  

  • 70. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
    Mannucci PM; Shi Q; Bonanad S; Klamroth R
    Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate?
    Berntorp E
    Hamostaseologie; 2017 Jan; 37(1):53-57. PubMed ID: 27878207
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Acquired hemophilia in the patient suffering from rheumatoid arthritis: case report.
    Drobiecki A; Pasiarski M; Hus I; Sokołowska B; Wątek M
    Blood Coagul Fibrinolysis; 2013 Dec; 24(8):874-80. PubMed ID: 24042266
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies.
    Santagostino E; Young G; Carcao M; Mannucci PM; Halimeh S; Austin S
    Expert Rev Hematol; 2018 Feb; 11(2):87-97. PubMed ID: 29258406
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Status and advances of long-acting factor Ⅷ].
    Lu D; Zeng F
    Sheng Wu Gong Cheng Xue Bao; 2018 Jan; 34(1):34-43. PubMed ID: 29380569
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The safety of pharmacologic options for the treatment of persons with hemophilia.
    Franchini M; Mannucci PM
    Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Inhibitor hemophilia A--diagnostic and therapeutic significance of controlled substitutions with factor VIII].
    Weippert M; Anders O; Schmidt M; Roewer J
    Beitr Infusionsther; 1990; 26():174-8. PubMed ID: 1703823
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Perioperative use of recombinant activated factor VII (rF VIIa) in a patient with hemophilia A having inhibitors].
    Kawasaki Y; Saeki N; Kawamoto M; Yuge O; Fujii T
    Masui; 2005 Aug; 54(8):926-8. PubMed ID: 16104555
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.
    Oldenburg J; Lacroix-Desmazes S; Lillicrap D
    Haematologica; 2015 Feb; 100(2):149-56. PubMed ID: 25638804
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors.
    Lozier JN; Santagostino E; Kasper CK; Teitel JM; Hay CR
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):10-21. PubMed ID: 8480192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.